Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
PURPOSE: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities. METHODS: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication. RESULTS: A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia. CONCLUSIONS: The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To aid future development of new therapeutic targets for sarcopenia, recommendations for the conduct of clinical trials have been developed, along with the proposal for a core outcome set to include the domains of activity/independence, quality of life, costs, and muscle mass, strength and performance [105,106].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033 · cited 1×
“Probably the most suitable instrument at the present time is the SF-36 [72], since it adequately covers the three key domains (physical/occupational function, social health/integration, and mental health/ psychological state), is not too onerous to complete, is well known and has proved suitable in more than one sarco…”
BackgroundFrailty in Older Adults: Evidence for a Phenotype
Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W. J., Burke, G., et al. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.3.m146 · Cited by 24,907
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601 · cited 4×
“In the words of the European Working Group on Sarcopenia in Older People (EWGSOP), sarcopenia is a condition ‘characterized by progressive and generalized loss of skeletal muscle mass and strength, with a risk of adverse outcomes such as physical disability, poor quality of life and death’ [2].”
BackgroundInfluentialSelf-citationGuralnik, J. M., Simonsick, E. M., Ferrucci, L., Glynn, R. J., Berkman, L. F., Blazer, D. G., Scherr, P. A., & Wallace, R. B. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.2.m85 · Cited by 9,792 · cited 4×
“The concept of targeting such a population to slow or prevent the progression to sarcopenia might be considered as being similar to the recently completed LIFE study [53] in which older persons with a sedentary lifestyle and at high risk of mobility disability (Short Physical Performance Battery [SPPB] score \10) but…”
BackgroundInfluentialThe metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Gait speed and survival in older adults.
Studenski, S. (2011) · JAMA · doi:10.1001/jama.2010.1923 · Cited by 4,558 · cited 1×
“8 m/s [2, 30]; below this level there is a strong association with reduced survival and increased risk of disability [31–34].”
BackgroundSelf-citationSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 1×
“It is likely that different thresholds may also have to be made for different ethnic groups [37, 38].”
BackgroundEpidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 1×
“Since, ALM varies according to body size, it is often indexed to the square of body height and thresholds applied by, for example, a rule of two standard deviations below a reference population [43] (giving cut-offs of \5.”
Method
Cited by
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
“A wide variety of tests and tools are now available for characterisation of sarcopenia in practice and in research (Table 2) [38, 39].”
BackgroundSelf-citationSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Self-citationSarcopenia in daily practice: assessment and management
Beaudart, C., McCloskey, E., Bruyère, O., Cesari, M., Rolland, Y., Rizzoli, R., Araujo de Carvalho, I., Amuthavalli Thiyagarajan, J., Bautmans, I., Bertière, M.-C., et al. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0349-4 · Cited by 850
Self-citationGale, C. R., Westbury, L., & Cooper, C. (2018) · Age and Ageing · doi:10.1093/ageing/afx188 · Cited by 590
“Sarcopenia is a major contributor to risk of functional decline and physical frailty [23].”
BackgroundSelf-citationBeaudart, C., Rolland, Y., Cruz-Jentoft, A. J., Bauer, J. M., Sieber, C., Cooper, C., Al-Daghri, N., Araujo de Carvalho, I., Bautmans, I., Bernabei, R., et al. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00545-w · Cited by 528
Self-citation
Metadata
- Authors
- Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H. A., Boers, M., Brandi, M. L., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R. A., Gasparik, A. I., Van Loon, L., McCloskey, E., Mitlak, B. H., Pilotto, A., Reiter-Niesert, S., Rolland, Y., Tsouderos, Y., Visser, M., & Cruz-Jentoft, A. J.
- Affiliations
- University of Liège (BE)
- University of Oxford (GB)
- University of Geneva (CH)
- Columbia University Irving Medical Center (US)
- Vrije Universiteit Brussel (BE)
- University Hospital Zurich (CH)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- University of Florence (IT)
- Istituto Nazionale di Riposo e Cura per Anziani (IT)
- University of Namur (BE)
- Tufts University (US)
- University of Sheffield (GB)
- Eli Lilly (United States) (US)
- Ente Ospedaliero Ospedali Galliera (IT)
- Université de Toulouse (FR)
- Institut de Recherches Internationales Servier (France) (FR)
- Vrije Universiteit Amsterdam (NL)
- Hospital Universitario Ramón y Cajal (ES)
- Corresponding author
- Bruyère, Olivier
- ORCID
- Venue
- Aging Clinical and Experimental Research
- Published
- 2015-12-30
- Volume
- 28
- Issue
- 1
- Pages
- 47-58
- ISSN
- 1594-0667 (ISSN-L)
- 1720-8319
- PMC
- PMC4768478
- OpenAlex
- W2214973932
- Cited by
- 112
- References
- 93
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 15 · 2023: 8 · 2022: 15 · 2021: 12 · 2020: 7 · 2019: 13 · 2018: 14 · 2017: 16 · 2016: 10
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Aging Clinical and Experimental Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- VU Research Portal (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Medical Research and Materiel Command, U.S. Army Medical Department
- US Department of Agriculture
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- sarcopenia, clinical trial design, drug development, sarcopenia prevention, core outcome set, clinical trial endpoints, patient selection criteria, sarcopenia prevalence, regulatory guidelines, frailty, older adults
- MeSH terms
- Aged, Clinical Trials as Topic, Humans, Research Design, Practice Guidelines as Topic, Medication Therapy Management, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. https://app.cochat.ai/papers/10.1007/s40520-015-0517-y
- The paper
- Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H. A., Boers, M., Brandi, M. L., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R. A., Gasparik, A. I., Van Loon, L., McCloskey, E., Mitlak, B. H., Pilotto, A., Reiter-Niesert, S., . . . Cruz-Jentoft, A. J. (2016). Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-015-0517-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
